Trial Profile
Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients With COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Cyclophosphamide (Primary) ; Pentostatin (Primary) ; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
- Indications Sickle cell anaemia
- Focus Adverse reactions; Therapeutic Use
- 05 Mar 2024 Planned End Date changed from 31 Dec 2024 to 17 Nov 2024.
- 05 Mar 2024 Planned primary completion date changed from 31 Dec 2024 to 17 Nov 2024.
- 02 Mar 2023 Status changed from recruiting to active, no longer recruiting.